MetaCap

Aspen Neuroscience (ASPE) vs Puma Biotechnology (PBYI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Puma Biotechnology is the larger company by market cap ($364.5 million vs $361.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASPE-16.59%PBYI-32.47%
+4%-15%-34%
Oct 30, 20261 yearNov 20, 2026
ASPE-16.59%PBYI-32.47%
+2%-16%-34%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASPE versus PBYI key metrics
MetricASPEPBYI
Share price$12.42$7.05
Market cap$361.16M$364.47M
1-day change+0.24%-0.98%
YTD return—+18.49%
1-year return—+44.17%
5-year return—+118.27%
P/E ratio (TTM)—15.33
Forward P/E—20.14
EPS (TTM)$-4.89$0.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$228.37M
Revenue growth (YoY)—-0.91%
Net income (latest FY)—$31.11M
Gross margin—74.53%
Operating margin—16.33%
Net margin—13.62%
52-week high$14.90$11.50
52-week low$11.20$4.84
Distance from 52-week high-16.64%-38.70%
Analyst consensus—none
Average volume352.42K387.40K
Shares outstanding29.08M51.70M
Employees120179
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aspen Neuroscience

ASPE stock →

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Puma Biotechnology

PBYI stock →

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees

ASPE vs PBYI FAQ

Which is bigger, Aspen Neuroscience or Puma Biotechnology?

Puma Biotechnology (PBYI) is larger, with a market capitalization of $364.47M compared with $361.16M for Aspen Neuroscience (ASPE).

Are Aspen Neuroscience and Puma Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons